title: The efficacy of the appetite suppressant, diethylpropion, is dependent on both when it is given (day vs. night) and under conditions of high fat dietary restriction.
abstract: Obesity is a public health problem caused by excessive consumption of high caloric diets and/or lack of physical activity. Although treatments for obesity include low caloric diets and exercise programs, these activities frequently are supplemented with appetite suppressants. For the short-term treatment of weight loss, diethylpropion (DEP) is a commonly used appetite suppressant. However, little is known with regard to how to improve its weight loss efficacy. We therefore evaluated, in rats, two administration protocols where the animals received daily injections of DEP. First, when these nocturnal animals were normally active (at night) and when they were normally inactive (daytime), and second, with or without high fat dietary restriction (HFDR). We observed that DEP induced a greater weight-loss administered when the animals were in their active phase than in their inactive phase. Moreover, DEP's administration during the inactive phase (and to a lesser degree in the active phase) promotes the consumption of food during normal sleeping time. In addition, we found that DEP-induced weight loss under ad libitum access to a HF diet, but its efficacy significantly improved under conditions of HFDR. In summary, the efficacy of DEP, and presumably other like appetite suppressants, is enhanced by carefully controlling the time it is administered and under dietary restriction of HF diets.
authors: Laboratory of Neurobiology of Appetite; Department of Pharmacology, CINVESTAV-IPN, 07360 Mexico City, Mexico.
authors: B
authors: B
authors: Kalyanasundar
authors: Laboratory of Neurobiology of Appetite; Department of Pharmacology, CINVESTAV-IPN, 07360 Mexico City, Mexico.
authors: Jessica
authors: J
authors: Solorio
authors: Laboratory of Neurobiology of Appetite; Department of Pharmacology, CINVESTAV-IPN, 07360 Mexico City, Mexico.
authors: Claudia I
authors: CI
authors: Perez
authors: Laboratory of Neurobiology of Appetite; Department of Pharmacology, CINVESTAV-IPN, 07360 Mexico City, Mexico.
authors: Carlos
authors: C
authors: Hoyo-Vadillo
authors: Department of Neurobiology, Duke University Medical Center, Durham, NC 27710, USA.
authors: Sidney A
authors: SA
authors: Simon
authors: Laboratory of Neurobiology of Appetite; Department of Pharmacology, CINVESTAV-IPN, 07360 Mexico City, Mexico. Electronic address: ranier@cinvestav.mx.
authors: Ranier
authors: R
authors: Gutierrez
mesh_terms: D000818:Animals; D001067:Appetite Depressants / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001069:Appetite Regulation / Q000187:drug effects*; D001711:Biotransformation; D002940:Circadian Rhythm / Q000187:drug effects; D003131:Combined Modality Therapy / Q000009:adverse effects; D018752:Diet, Fat-Restricted; D059305:Diet, High-Fat / Q000009:adverse effects; D004038:Diet, Reducing; D004053:Diethylpropion / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D002149:Energy Intake / Q000187:drug effects; D006207:Half-Life; D007274:Injections, Intraperitoneal; D008297:Male; D050177:Overweight / Q000097:blood / Q000178:diet therapy / Q000188:drug therapy* / Q000209:etiology; D010665:Phenylpropanolamine / Q000031:analogs & derivatives / Q000097:blood; D017207:Rats, Sprague-Dawley; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D001067:Appetite Depressants; C005341:N-ethylaminopropiophenone; D010665:Phenylpropanolamine; C005343:N-diethylnorpseudoephedrine; D004053:Diethylpropion
keywords: Appetite suppressant; High fat diet; Night eating like syndrome; Obesity